Ohr Pharmaceutical, Inc. (OHRP)

Oncology Corporate Profile

Stock Performance

0.8800
0.0000

HQ Location

489 5th Avenue, 28th Floor
New York, NY 10017

Company Description

Ohr Pharmaceutical, Inc. is a pharmaceutical company dedicated to the development of first-in-class drugs for under-served therapeutic needs. Ohr is focused on the development of novel pharmaceuticals for the treatment of serious and unmet medical needs. Our lead product is Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet AMD) with a potential for expansion into other indications such as diabetic macular edema (DME) and retinal vein occlusions (RVO). Wet-AMD is a leading cause of vision loss and blindness in the elderly, affecting over 1.75 million patients in the United States alone. Squalamine is currently being tested in a Phase 2 clinical trial in patients with wet AMD and may offer an alternative to individuals who wish to reduce or eliminate intravitreal injections that are required with currently available treatments. Our second product is OHR/AVR 118 for the treatment of Cancer Cachexia. Cancer Cachexia, or wasting syndrome, is characterized by symptoms of loss of appetite and body weight, fatigue, and loss of muscle mass. It is a debilitating condition that affects many late-stage cancer patients and greatly diminishes their quality of life.

Website: http://www.ohrpharmaceutical.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
OHR / AVR 118immunomodulatorCancer cachexiaII
squalaminesmall molecule anti-agiogenicOvarian cancerII

View additional information on product candidates here »

Source


http://www.ohrpharmaceutical.com

Recent News Headlines

Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference

3/2/2017 02:03 pm

[GlobeNewswire] - NEW YORK, March 02, 2017-- Ohr Pharmaceutical, Inc., a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive ...

Ohr Pharmaceutical Announces Strategic Update and Fiscal First Quarter 2017 Earnings

2/14/2017 12:00 pm

[GlobeNewswire] - Management to Host a Conference Call and Webcast at 7:45a.m Eastern Time Today. NEW YORK, Feb. 14, 2017-- Ohr Pharmaceutical, Inc., a clinical-stage pharmaceutical company developing novel therapies for ...

Ohr Pharmaceutical to Announce First Quarter 2017 Financial Results on February 14

2/13/2017 03:03 pm

[GlobeNewswire] - NEW YORK, Feb. 13, 2017-- Ohr Pharmaceutical, Inc., an ophthalmology research and development company, today announced that it will report financial results for its first fiscal quarter ended December ...

Post Earnings Coverage as Ohr Pharma Reported Annual Results; Announced Closure of Public Offering

1/5/2017 01:01 pm

[Accesswire] - Upcoming AWS Coverage on Seattle Genetics Post-Earnings Results LONDON, UK / ACCESSWIRE / January 5, 2017 / Active Wall St. announces its post-earnings coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP ...

Ohr Pharmaceutical Reports Fiscal Year 2016 Financial and Business Results

12/22/2016 09:03 pm

[at noodls] - Conference Call Today at 5:00pm Eastern Time NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results ...

Ohr Pharmaceutical Reports Fiscal Year 2016 Financial and Business Results

12/22/2016 09:00 pm

[GlobeNewswire] - NEW YORK, Dec. 22, 2016-- Ohr Pharmaceutical, Inc., an ophthalmology research and development company, today reported results for its fourth quarter and fiscal year ended September 30, 2016.. “Fiscal year ...

Ohr Pharmaceutical to Announce Fourth Quarter and Fiscal 2016 Financial Results on December 22

12/15/2016 07:01 pm

[GlobeNewswire] - NEW YORK, Dec. 15, 2016-- Ohr Pharmaceutical, Inc., an ophthalmology research and development company, today announced that it will report financial results for the fiscal year ended September 30, 2016 ...

Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants

12/14/2016 01:00 pm

[GlobeNewswire] - NEW YORK, Dec. 14, 2016-- Ohr Pharmaceutical, Inc., an ophthalmology research and development company, today announced that it has closed its previously announced public offering of common stock and warrants. ...

Ohr Pharmaceutical, Inc. Announces Pricing of $7.75 Million Public Offering of Common Stock and Warrants

12/8/2016 01:00 pm

[GlobeNewswire] - NEW YORK, Dec. 08, 2016-- Ohr Pharmaceutical, Inc., an ophthalmology research and development company, today announced that it has priced a registered public offering of an aggregate of 3,875,000 shares ...